Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology.
about
Experimental treatment of antipsychotic-induced movement disordersTardive dyskinesia: therapeutic options for an increasingly common disorder.Neurology issues in schizophrenia.Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study.Medication-Induced Tardive Dyskinesia: A Review and Update.Case report of refractory tardive dystonia induced by olanzapine.Tardive Syndromes are Rarely Reversible after Discontinuing Dopamine Receptor Blocking Agents: Experience from a University-based Movement Disorder Clinic.NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study.Drug-Induced Dyskinesia, Part 2: Treatment of Tardive Dyskinesia.Remission of irreversible aripiprazole-induced tardive dystonia with clozapine: a case report.Naturalistic study of guideline implementation tool use via evaluation of website access and physician survey.Tardive dyskinesia occurring in a young woman after withdrawal of an atypical antipsychotic drug.Off-label antipsychotic use and tardive dyskinesia in at-risk populations: new drugs with old side effectsTardive dyskinesia in patients treated with atypical antipsychotics: case series and brief review of etiologic and treatment considerations.Oxidative stress and the antipsychotic-induced vacuous chewing movement model of tardive dyskinesia: evidence for antioxidant-based prevention strategies.Emerging drugs for antipsychotic-induced tardive dyskinesia: investigational drugs in Phase II and Phase III clinical trials.Identification and management of tardive dyskinesia: A case series and literature review.Pharmacological treatment of tardive dyskinesia: recent developments.Pharmacotherapy for the treatment of tardive dyskinesia in schizophrenia patients.Therapeutic Perspective on Tardive Syndrome with Special Reference to Deep Brain Stimulation.Tardive Dystonia Related with Aripiprazole.Aripiprazole-induced Tardive Dyskinesia in 13 Years Old Girl Successfully Treated with Biperiden: A Case Report.Psychosis After Switch in Opioid Maintenance Agonist and Risperidone-Induced Pisa Syndrome: Two Critical Incidents in Dual Diagnosis Treatment.MSBIS: A Multi-Step Biomedical Informatics Screening Approach for Identifying Medications that Mitigate the Risks of Metoclopramide-Induced Tardive Dyskinesia.Movement disorders and chronic psychosis: Five new things.Tardive dyskinesia: motor system impairments, cognition and everyday functioning.Valbenazine for the treatment of tardive dyskinesia.Deutetrabenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?Treatment of tardive dyskinesia with tetrabenazine or valbenazine: a systematic review.Treatment options for chorea.Melatonin enhances L-DOPA therapeutic effects, helps to reduce its dose, and protects dopaminergic neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice.Valbenazine (Ingrezza): The First FDA-Approved Treatment for Tardive Dyskinesia.Schizophrenia and Other PsychosesHospital utilization rates following antipsychotic dose reductions: implications for tardive dyskinesiaManagement of common adverse effects of antipsychotic medications
P2860
Q26740354-5A6C5C23-ED5A-4BE5-949E-F85514EC9054Q30566749-4772954B-3B0C-4085-9E80-7BAB6648DD5FQ30910367-F53E7D32-FE9D-4F34-899A-90F42C329135Q33714619-5D6B4905-DADD-4696-91C2-D74C52E707BDQ33802645-47759E9E-8EC3-4AB9-86FF-2E7A379FF5E3Q33984813-D6938DE0-B99C-4828-891E-A91D0D9BF826Q34447349-43C1EDF8-F919-4474-9C52-468F9297EAE5Q34492934-B5C42C77-0037-4F1B-AEB6-CC6FF1252B28Q34522634-435FC3C6-267D-43EA-87BF-BC3080D010D3Q35813662-9C9ED635-ECE7-49FE-8F0B-78C21E7201B7Q36249197-4A3514CD-D944-4EE3-B095-D1D7823A0B43Q36504557-62BA02B1-BF2A-429F-9742-E32222A9F401Q37416376-D31D67F5-6F24-4422-BC51-E2103B2A2443Q37707292-056A9C9F-2B5E-40C2-84E2-2ED0CADD6C35Q38206130-A63917EC-030A-48F6-B901-3C5244C36266Q38545655-9A353A11-CA2C-47A7-9E0F-D1D812DFBE08Q38555637-2F0E4246-DF69-4D40-BAB2-72AD8895469CQ38670290-0B667759-1D88-4B6D-B43B-740B3DEE7F9CQ38819771-4787466F-2049-4434-B086-4AD9337EC5E7Q39084564-653465A2-67F6-437D-B9E0-E514528C9E1FQ41954813-251CBBA5-83BF-48CF-BD7C-C5E055A9C420Q42348171-F1558AD3-D54B-44B0-9812-8387D4BED565Q44341865-62CC131C-59B6-4EF6-90F5-A0E655B11F3AQ47225742-17190DB1-65A5-4714-85E1-B0342C421C0AQ47398683-AEA05BBE-F01E-4030-92C0-249B9B35DAC3Q47628451-7A487AC8-C348-4A01-B9AA-C7006E20F520Q47670227-2C94DFC3-6A9B-4C32-A3C7-47370A62AA00Q47675010-AF5A1179-9D43-4CD9-A2BC-4A252434A735Q47753620-17065760-2873-4C15-B1AC-4D2D751EF966Q47977953-41139947-0368-4B9B-B8C6-6A3DC2C04F9BQ48357495-341F6FE3-649B-4C3D-B770-EE189A930AEAQ55415826-937D4BD3-931B-4C1D-943A-86B47775C253Q56061326-F911A137-4511-4E27-A43B-00DADCC98965Q58700947-7154A683-7DAB-4666-86FC-6F25A1500637Q58760350-8044FD31-66E7-4D7E-BD1B-F191AF335E99
P2860
Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Evidence-based guideline: trea ...... American Academy of Neurology.
@en
type
label
Evidence-based guideline: trea ...... American Academy of Neurology.
@en
prefLabel
Evidence-based guideline: trea ...... American Academy of Neurology.
@en
P2093
P1433
P1476
Evidence-based guideline: trea ...... American Academy of Neurology.
@en
P2093
American Academy of Neurology
Gary S Gronseth
Kelly L Sullivan
Theresa A Zesiewicz
William J Weiner
P304
P356
10.1212/WNL.0B013E31829D86B6
P407
P577
2013-07-01T00:00:00Z